By bizn_fun 
Eli Lilly also said in a statement it would escape tariffs for three years as part of the agreement with the Trump administration.
An estimated 10% of Medicare beneficiaries will be eligible for expanded access to GLP-1 drugs, and will only pay $50, according to senior administration officials.
Those enrolled in Medicaid will see a rolling start date based on when states sign up to participate, the officials said.
Trump has long pushed for “most-favoured nations” prices – a policy aimed at aligning drug prices in the US with lower ones abroad.
The obesity drugs will be sold at discounted prices on the direct-to-consumer TrumpRx, a government-run website set to launch by January.
On TrumpRx, Wegovy and Zepbound will start at $350 per month on average, and drop to $250 within two years, administration officials said. The Medicare prices of Ozempic, Wegovy, Mounjaro and Zepbound will be $245.
Along with Novo Nordisk’s Wegovy, Eli Lilly’s weight loss pill, orforglipron, will be sold for $149 for the lowest dose, Eli Lilly said in a statement. The company’s Zepbound medication will cost $299 for a starting dose.
Those prices are dependent on Food and Drug Administration approval of the pills.
“Lilly is in a unique position to work with the US government to rebalance the global system, expand access and lower costs for Americans,” David Ricks, Eli Lilly’s chief executive, said in a statement.